Researchers at Oregon Health & Science University reported long-term suppression of SHIV replication in macaques using an AAV gene therapy encoding a CCR5-blocking antibody derived from leronlimab. The work was published in Science Translational Medicine. In the study, 19 SHIV-infected macaques received AAVs expressing the leronlimab antibody. Most animals produced detectable antibody levels after dosing; about half developed anti-drug antibodies, but expression persisted long enough to show partial or full SHIV suppression in those animals meeting response thresholds. The findings add to the evidence base for functional cure concepts that rely on sustained anti-entry blockade, while underscoring immunogenicity as a practical design constraint for AAV-delivered antibody approaches.